Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Phase I dose-escalation study of procaspase-activating compound-1 in combination with temozolomide in patients with recurrent high-grade astrocytomas

Neuro-Oncology Advances(2023)10.1093/noajnl/vdad087Source: DataRank Database

Phase I dose-escalation study of procaspase-activating compound-1 in combination with temozolomide in patients with recurrent high-grade astrocytomas is a research paper published in Neuro-Oncology Advances (2023). On theSindex it has a DataRank of 0. It has been cited 7 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access7 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 1.15)OA: goldTopics (25)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (15)

M. Kelly Nicholas,Richard A. Peterson ORCID,Stefania Maraka ORCID,Li Liu ORCID,James H. Fischer ORCID

Live enrichment

PubMed:37554223 PMC:PMC10406430 OpenAlex:https://openalex.org/W4384825853

National Institutes of Health

Grant: R01CA120439

National Institutes of Health

Grant: P30CA006973

National Institutes of Health

Grant: 3P30CA006973-53S2

Regional Oncology Research Center

National Institutes of Health

Grant: 4R01CA120439-09

Small Molecule Activators of Procaspases as Anti-Cancer Agents

FWCI

1.15

Citation Percentile

0.8%

Citation Trend

2024

2025

2026

goldLicense: cc-by

journalhttps://academic.oup.com/noa/advance-article-pdf/doi/10.1093/noajnl/vdad087/50910011/vdad087.pdf

publisherhttps://academic.oup.com/noa/advance-article-pdf/doi/10.1093/noajnl/vdad087/50910011/vdad087.pdf

publisherhttps://academic.oup.com/noa/article-pdf/5/1/vdad087/51049544/vdad087.pdf

journalhttps://doi.org/10.1093/noajnl/vdad087

repositoryhttps://pubmed.ncbi.nlm.nih.gov/37554223

Fields of Study

Glioma Diagnosis and TreatmentPARP inhibition in cancer therapyCell death mechanisms and regulation03 medical and health sciences0302 clinical medicine

Keywords

TemozolomideMedicineTolerabilityInternal medicineToxicityGliomaOncologyGastroenterologyMethyltransferaseChemotherapyPharmacologyAdverse effectCancer researchBiologyAstrocytomaGlioblastomaRecurrencePac-1Procaspase-activating Compound-1Clinical Investigations

Sustainable Development Goals

SDG 0: Good health and well-being

Phase I dose-escalation study of procaspase-activating compound-1 in combination with temozolomide in patients with recurrent high-grade astrocytomas

FAIR Checklist

Authors (15)

Funding (4 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)